The Beauty Health Company
SKIN evidence brief
What we can confirm
- BioSniper Score:
- 6.1 / 10
- Market Cap:
- $87.8M
- Lead Asset:
- hydrafacial (Approved)
What it means
What to watch
Prepared research question
What matters most for SKIN—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · SKIN
The Beauty Health Company (SKIN) is a global medical aesthetics company anchored by the Hydrafacial brand, delivering an integrated ecosystem of clinically proven skincare solutions including device technology and proprietary consumables [sec_mda · as of 2026-08-06].
Key risk: Macroeconomic exposure
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$87.8M
Cash Runway
—
Lead Asset
hydrafacial (Approved)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 1 clinical trial for The Beauty Health Company.
The Beauty Health Company (SKIN) is a global medical aesthetics company anchored by the Hydrafacial brand, delivering an integrated ecosystem of clinically proven skincare solutions including device technology and proprietary consumables [sec_mda · as of 2026-08-06].
- Total revenue of $72.1M and net income of -$2.7M as of 2026-06-30 [sec].
- Shareholders' equity of $55.6M as of 2026-06-30 [sec].
- Anchored by Hydrafacial, a leading professional skincare treatment, and supported by SkinStylus microneedling and HydraScalp powered by Keravive [sec_mda · as of 2026-08-06].
- Q3 2025 revenue of $70.7 million and Adjusted EBITDA of $8.9 million [news · published 2025-11-07].
What works
- Strong brand anchored by Hydrafacial, a widely requested professional skincare treatment [sec_mda · as of 2026-08-06].
- Integrated ecosystem combining advanced device technology, proprietary consumables, and clinical validation [sec_mda · as of 2026-08-06].
- Disciplined execution reflected in Q3 2025 results with revenue of $70.7M and Adjusted EBITDA of $8.9M [news · published 2025-11-07].
What to weigh
- Net loss of -$2.7M as of 2026-06-30 indicates ongoing profitability challenges [sec].
- Business exposed to global economic conditions including inflation, recession, and higher interest rates that may impact customer financing and sales cycles [sec_mda · as of 2026-08-06].
- Increased competition and market conditions affecting ability of potential customers to obtain credit on acceptable terms [sec_mda · as of 2026-08-06].
From the filings
Quoted directly from source documents.
Company is a global medical aesthetics company anchored by Hydrafacial
“SkinHealth Systems Inc. (the "Company" or "SkinHealth Systems") is a global medical aesthetics company delivering an integrated ecosystem of clinically proven solutions designed to help consumers achieve superior skin health and support the success of providers. Anchored by Hydrafacial, a leading and widely requested professional skincare treatment”
SEC MD&A · August 6, 2026
Q3 2025 revenue and Adjusted EBITDA
“Revenue of $70.7 million and Adjusted EBITDA of $8.9 million exceeded”
News · November 7, 2025
Catalyst timeline
- 2026-08-06 · Earnings Report - SEC 8-K filing — Most recent earnings report filed; watch for updates on financial performance and management discussion.
Risks & what to watch (3)›
Key risks
- Macroeconomic exposure — Global economic conditions like inflation, recession, and higher interest rates may impact business unpredictably [sec_mda · as of 2026-08-06].
- Profitability pressure — Net loss of -$2.7M as of 2026-06-30 indicates ongoing profitability challenges [sec].
- Competitive and credit risks — Increased competition and interest rate environment affecting customer credit access and sales cycles [sec_mda · as of 2026-08-06].
What to watch
- Future earnings reports and financial results for continued profitability trends [catalyst].
- Impact of macroeconomic conditions on sales cycles and customer financing [sec_mda · as of 2026-08-06].
- Progress of science-backed innovation product pipeline and global infrastructure optimization [sec_mda · as of 2026-08-06].
Sources: Catalysts · Competitor trials · News · SEC MD&A · Generated October 13, 2026 · How we verify sources →
Run The Beauty Health Company through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available The Beauty Health Company facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
D/E 7.76 · 0% dilution
Lead: Approved
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Financials
Short Interest
as of May 19, 2026- % of float
- 35.4%
- Days to cover
- 26.0
- Shares short
- 16,529,329
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
SKIN short interestGovernance
Frequently asked questions
What is the AI investment thesis for The Beauty Health Company?
The Beauty Health Company (SKIN) is a global medical aesthetics company anchored by the Hydrafacial brand, delivering an integrated ecosystem of clinically proven skincare solutions including device technology and proprietary consumables [sec_mda · as of 2026-08-06].
What is The Beauty Health Company's lead drug candidate?
The Beauty Health Company's most advanced tracked candidate is hydrafacial (Approved) for Skin health, including cleansing, extraction, and hydration.
Who is the CEO of The Beauty Health Company?
Mr. Pedro Malha is the chief executive officer of The Beauty Health Company (SKIN).
Where is The Beauty Health Company headquartered?
The Beauty Health Company (SKIN) is headquartered in Long Beach, CA, United States.
What therapeutic areas does The Beauty Health Company focus on?
The Beauty Health Company develops therapies across Dermatology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.